Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03206762
Recruitment Status : Enrolling by invitation
First Posted : July 2, 2017
Last Update Posted : August 7, 2018
Sponsor:
Information provided by (Responsible Party):
Midwest Cardiovascular Research Foundation

Brief Summary:
A prospective, multicenter, randomized study evaluating the use of Jetstream Atherectomy (JS) followed by DCB in comparison to the use of plain old balloon angioplasty (POBA) followed by DCB alone in the treatment of complex lesions in femoropopliteal arteries in subjects with claudication (Rutherford Clinical Category (RCC) of 2-4) (complex lesions are defined as long (≥ 10 cm) lesions, or moderately or highly calcified lesions, or chronic total occlusions irrespective of length).

Condition or disease Intervention/treatment Phase
Peripheral Vascular Disease Device: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 255 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 255 subjects are planned for enrollment (with a block 2:1 randomization)
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: JETStream AtheRectomy With Adjunctive Paclitaxel-Coated BallooN Angioplasty vs Balloon AnGioplasty Followed by Paclitaxel-Coated Balloon in Treating ComplEx Denovo FemoRopopliteal Arterial Disease (JET-RANGER)
Actual Study Start Date : March 28, 2018
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angioplasty
Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB
Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
Device: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm

Active Comparator: POBA+DCB (Ranger or IN.PACT)
POBA and then DCB treatment (Ranger or IN.PACT)
Device: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm




Primary Outcome Measures :
  1. Target Lesion Revascularization [ Time Frame: 1 year ]
    Effectiveness: Target Lesion Revascularization at 1 Year: TLR is defined as retreatment of the index lesion (extended 1 cm proximal and distal to the lesion) at 1 year. For the primary endpoint, intra-procedural bail out stenting of the index lesion is considered meeting a TLR endpoint. (ITT analysis)

  2. Major Adverse Events [ Time Frame: 30 Days ]
    Safety: Major Adverse Events (MAE) at 30 days: unplanned amputation, total mortality or TLR at 30 days (TLR includes bail out stenting)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subject must meet all of the following general inclusion criteria.

  1. Has a Rutherford Clinical Category of 2 - 4.
  2. Is willing and capable of complying with all follow-up evaluations at the specified times (including an angiogram at the 1-year follow-up visit).
  3. Is ≥ 18 years old.
  4. Is able and willing to provide written informed consent prior to study specific procedures.

Angiographic Inclusion Criteria:

Subject must meet all of the following angiographic inclusion criteria. Unless otherwise specified, the Investigator performing the procedure bases all angiographic inclusion criteria on visual determination at the time of the procedure.

  1. Has evidence at the target lesion of ≥ 70% de novo stenosis of a. ≥ 10 cm length, or b. any chronic total occlusion (> 1 month by history or known by conventional or CT angiography or arterial duplex ultrasound) in the SFA (at least 1 cm from the bifurcation of the profunda) and/or popliteal artery, or 3. at least grade 2 or higher calcification as defined by the peripheral arterial calcium scoring system (PACCS)26
  2. Has evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not have significant (< 70%) stenosis during the index procedure.
  3. Has a reference vessel diameter of 4 - 7 mm.
  4. Has a target lesion an exchangeable guidewire can cross via the true lumen (without using a re-entry device or a subintimal approach).

General Exclusion Criteria:

The subject must not meet any of the following general exclusion criteria.

  1. Has one or more of the contraindications listed in the JetStream or Ranger IFUs.
  2. Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used (that cannot be reasonably substituted).
  3. Is expected to require cilostazol (Pletal) during the one-year follow-up period.
  4. Has a hypersensitivity to contrast material that cannot be adequately pretreated.
  5. Has known hypersensitivity to treatment device materials including paclitaxel or nitinol.
  6. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion.
  7. Has life expectancy of less than 24 months.
  8. Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing.
  9. Has surgical or endovascular procedure of the target vessel within 30 days prior to the index procedure.
  10. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure.
  11. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes.
  12. Has any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention.
  13. Has had a previous peripheral bypass affecting the target vessel (allowable for physician to pass through bypass graft in aorta-iliac region to get to the target lesion).
  14. Has chronic renal insufficiency (eGFR < 30 ml/min or creatinine ≥ 2.5 including dialysis patients).
  15. Has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure.
  16. Has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure.
  17. Has had a stroke within 3 months prior to index procedure.
  18. Has had a myocardial infarction within 1 month prior to index hospitalization
  19. Has history of significant gastrointestinal bleeding in the past 2 months prior to index procedure, or any history of hemorrhagic diathesis.
  20. Has a known or suspected systemic infection at the time of the index procedure.
  21. Patients with ipsilateral Iliac and CFA disease are allowed in the study but these lesions have to be treated successfully first (<30% residual) before patient can be enrolled. Treatment as per investigator's preference.
  22. Aneurysm located in the target vessel or aneurysmal vessel

Angiographic Exclusion Criteria:

The subject must not meet any of the following angiographic exclusion criteria. The Investigator performing the procedure bases all angiographic exclusion criteria on visual determination at the time of the procedure.

  1. Has < 70% stenosis prior to treatment of the target lesion.
  2. Has in-stent restenosis of the target lesion.
  3. Has an acute intraluminal thrombus within the target lesion.
  4. Has an aneurysmal target vessel
  5. Patient has already been enrolled in the study or any other study that by the investigator judgment may interfere with the outcome of this trial
  6. Has two or more lesions that require treatment in the target vessel. Lesions have to be separated by > 5 cm in order to be considered different lesions. Only one lesion per target vessel can be enrolled during the index procedure
  7. Has disease that precludes safe advancement of the JS device to the target lesion.
  8. P3 segments of the popliteal vessel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03206762


Locations
Layout table for location information
United States, Iowa
Midwest Cardiovascular Research Foundation
Davenport, Iowa, United States, 52803
Sponsors and Collaborators
Midwest Cardiovascular Research Foundation
Investigators
Layout table for investigator information
Study Director: Nicolas Shammas, MD, Research Director MCRF

Layout table for additonal information
Responsible Party: Midwest Cardiovascular Research Foundation
ClinicalTrials.gov Identifier: NCT03206762     History of Changes
Other Study ID Numbers: MCRF-S-001-2015
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action